Published on January 28, 2010 at 8:05 AM
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced initiation of
a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like
Receptor (TLR) 7 and TLR9.
“IMO-3100 is our fourth
compound to advance into clinical development, each for a different
therapeutic application.”
“As an antagonist of TLR7 and TLR9, IMO-3100 has a novel mechanism of
action and presents a potentially innovative approach in the treatment
of a number of autoimmune diseases,” said Sudhir Agrawal, D.Phil., Chief
Executive Officer and Chief Scientific Officer. “IMO-3100 is our fourth
compound to advance into clinical development, each for a different
therapeutic application.”
“Our first step in the clinical evaluation of IMO-3100 is to assess the
safety and mechanism of action in healthy subjects,” said Tim Sullivan,
Ph.D., Vice President of Development Programs. “We have observed
exciting results that show IMO-3100 ameliorates the pathologic findings
observed in preclinical models of various autoimmune diseases, including
lupus, rheumatoid arthritis, and psoriasis. Data from this Phase 1
clinical trial will support our decisions regarding subsequent clinical
development of IMO-3100.”
Source Idera Pharmaceuticals, Inc.